Compounds > 5-(2-iodovinyl)-2'-deoxyuridine
Page last updated: 2024-11-11

5-(2-iodovinyl)-2'-deoxyuridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-(2-iodovinyl)-2'-deoxyuridine: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6440124
CHEMBL ID223205
SCHEMBL ID1626547
SCHEMBL ID1626550
MeSH IDM0096083
PubMed CID6438371
MeSH IDM0096083

Synonyms (24)

Synonym
1-((2r,4s,5r)-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-((e)-2-iodo-vinyl)-1-h-pyrimidine-2,4-dione
(e)-5-(2-iodovinyl)-durd
ivdu
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-[(e)-2-iodovinyl]pyrimidine-2,4-dione
uridine, 2'-deoxy-5-(2-iodoethenyl)-, (e)-
uridine, 2'-deoxy-5-(2-iodovinyl)-, (e)-
brn 0758154
(e)-5-(2-iodovinyl)deoxyuridine
(e)-2'-deoxy-5-(2-iodovinyl)uridine
(e)-5-(2-iodovinyl)-2'-deoxyuridine
CHEMBL223205
unii-4wlk8jc9ar
69304-48-9
e-5-(2-iodovinyl)-2'-deoxyuridine
4wlk8jc9ar ,
SCHEMBL1626547
SCHEMBL1626550
DTXSID70219364
Q27260602
5-(2-iodovinyl)-2'-deoxyuridine
e-5-(2-iodovinyl)-durd
uridine, 2'-deoxy-5-(2-iodoethenyl)-
1-[(4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(z)-2-iodoethenyl]pyrimidine-2,4-dione
87727-68-2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID91297Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID91307Concentration of the drug required to reduce the uptake of neural red stain by uninfected cell monolayers (HFF)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID91306Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID87509Minimum inhibitory concentration (MIC) required to reduce HSV-1 strain (F) induced cytopathogenicity in primary rabbit kidney cell cultures1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID146667Minimum inhibitory concentration (MIC) required to inhibit proliferation of Novikoff rat hepatoma1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID87830Minimum inhibitory concentration (MIC) required to reduce HSV-2 strain G induced cytopathogenicity in primary rabbit kidney cell cultures1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID216193Dose to inhibit plaque formation in vero cells infected with herpes simplex virus type-1 (HSV-1,strainJLJ) was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine.
AID87510Minimum inhibitory concentration (MIC) required to reduce HSV-1 strain McIntyre induced cytopathogenicity in primary rabbit kidney cell cultures1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID144640Inhibition constant was determined for the facilitated transport of [3N]-thymidine by murine erythrocyte NBMPR-sensitive nucleoside transporter.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine.
AID91295Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID165905Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells; ND is Not Determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID87639Minimum inhibitory concentration (MIC) required to reduce thymidine kinase deficient HSV-1 induced cytopathogenicity in primary rabbit kidney cell cultures1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID93932Minimum inhibitory concentration (MIC) required to inhibit proliferation of murine leukemia L1210 (wild type)1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID222316Minimum inhibitory concentration (MIC) required to inhibit proliferation of human lymphoblast Raji1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID91301Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID85249Inhibitory activity against HSV-12003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID87511Minimum inhibitory concentration (MIC) required to reduce Herpes simplex virus (HSV-1) KOS strain induced cytopathogenicity in primary rabbit kidney cell cultures1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID91299Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine.
AID93930Minimum inhibitory concentration (MIC) required to inhibit proliferation of murine leukemia L1210 (TK-)1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID216379Minimum inhibitory concentration (MIC) required to reduce vesicular stomatis virus induced cytopathogenicity in primary rabbit kidney cell cultures1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID87829Minimum inhibitory concentration (MIC) required to reduce HSV-2 strain (Lyons) induced cytopathogenicity in primary rabbit kidney cell cultures1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID217835Minimum inhibitory concentration (MIC) required to reduce vaccinia virus induced cytopathogenicity in primary rabbit kidney cell cultures1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
AID85250Inhibitory activity against HSV-22003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID229018Inhibitory activity against vaccinia virus2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (69.70)18.7374
1990's5 (15.15)18.2507
2000's4 (12.12)29.6817
2010's1 (3.03)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.77 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.420nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
thymidine
[no description available]		2.0110pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.4320nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
idoxuridine
[no description available]		2.6930organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.0310pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
cytarabine
[no description available]		2.0310beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine
Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.		2.0310nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
isosorbide dinitrate
Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.		2.0110glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
deoxyuridine
[no description available]		1.9710pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		2.03106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
[no description available]		2.0310
thymine arabinoside
thymine arabinoside: selectively inhibits replication of herpes simplex virus		2.0310N-glycosyl compound
edoxudin
[no description available]		2.4120pyrimidine 2'-deoxyribonucleoside
n-(2-(hydroxyethoxy)methyl)-5-methyluracil
N-(2-(hydroxyethoxy)methyl)-5-methyluracil: structure given in first source		2.0310
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil: structure given in first source		2.0310
5-hydroxymethyl-2'-deoxyuridine
[no description available]		2.0310pyrimidine 2'-deoxyribonucleoside
msh release-inhibiting hormone
[no description available]		2.0310oligopeptide
5-hydroxy-2'-deoxyuridine
5-hydroxy-2'-deoxyuridine: a major oxidation product of 2'-deoxycytidine		2.0310
5-formyl-2'-deoxyuridine
5-formyl-2'-deoxyuridine: structure given in first source		2.0310
5-nitro-2'-deoxyuridine
[no description available]		2.0310
5-vinyl-2'-deoxyuridine
5-vinyl-2'-deoxyuridine: structure		2.0310
5-propyl-2'-deoxyuridine
5-propyl-2'-deoxyuridine: RN given refers to parent cpd		2.0310
adenosine-5'-carboxaldehyde
adenosine-5'-carboxaldehyde: potent inhibitor of S-adenosyl-L-homocysteine hydrolase; structure given in first source. 5'-dehydroadenosine : A member of the class of adenosines that is 5'-dehydro derivative of adenosine.		2.0310adenosines
brivudine
brivudine: anti-herpes agent		2.420
carbocyclic 5-iodo-2'-deoxyuridine
[no description available]		1.9610
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		1.9710L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
5-ethynyl-2'-deoxyuridine
5-ethynyl-2'-deoxyuridine: structure in first source		2.0310
5-cyano-2'-deoxyuridine
5-cyano-2'-deoxyuridine: structure in first source		2.0310
5-(2-chloroethyl)-2'-deoxyuridine
5-(2-chloroethyl)-2'-deoxyuridine: inhibitor of herpes viruses; structure given in first source		1.9710pyrimidine 2'-deoxyribonucleoside
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.68302-aminopurines;
oxopurine		antimetabolite;
antiviral drug
ganciclovir
[no description available]		1.98102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
9-((2-phosphonylmethoxy)ethyl)guanine
9-((2-phosphonylmethoxy)ethyl)guanine: structure given in first source		2.0310phosphoethanolamine
thymidine
[no description available]		2.3720pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.3920nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
idoxuridine
[no description available]		4.64280organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		3.75110pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
fluorodeoxyuridylate
Fluorodeoxyuridylate: 5-Fluoro-2'-deoxyuridylate. An inhibitor of thymidylate synthetase. Formed from 5-fluorouracil or 5-fluorodeoxyuridine.		1.9610pyrimidine 2'-deoxyribonucleoside 5'-monophosphate
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		1.9710cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
deoxyuridine
[no description available]		7.8840pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
bromine
Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested.		1.9610diatomic bromine
etoposide
[no description available]		1.9710beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
aminopterin
Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.		1.9610dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
brivudine
brivudine: anti-herpes agent		3.67100
bromodeoxycytidine
Bromodeoxycytidine: 5-Bromo-2'-deoxycytidine. Can be incorporated into DNA in the presence of DNA polymerase, replacing dCTP.		1.9610
1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1h,3h)-pyrimidinedione
1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1H,3H)-pyrimidinedione: RN & structure given in first source; RN refers to (E)-isomer		1.9710
5-(1-propenyl)-2'-deoxyuridine
5-(1-propenyl)-2'-deoxyuridine: has anti-herpes activity; structure in first source		1.9610
5-(2-iodovinyl)-1-(2'-fluoro-2'-deoxyuridine)
5-(2-iodovinyl)-1-(2'-fluoro-2'-deoxyuridine): structure given in first source		2.0210
i(3)so3-galactosylceramide
Sulfoglycosphingolipids: GLYCOSPHINGOLIPIDS with a sulfate group esterified to one of the sugar groups.. 1-(3-O-sulfo-beta-D-galactosyl)-N-tetracosanoylsphingosine : A D-galactosyl-N-acylsphingosine having a sulfo group at the 3-position on the galactose ring and tetracosanoyl as the N-acyl group.		1.9710galactosylceramide sulfate;
N-acyl-beta-D-galactosylsphingosine
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		1.97101,2-diacyl-sn-glycero-3-phosphocholine
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.66302-aminopurines;
oxopurine		antimetabolite;
antiviral drug
ganciclovir
[no description available]		2.05102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9710
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9710
Herpes Simplex Virus Infection
[description not available]		03.4780
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		08.4780
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		01.9810
Benign Neoplasms, Brain
[description not available]		02.0510
Astrocytoma, Grade IV
[description not available]		02.0510
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.0510
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.0510
Benign Neoplasms
[description not available]		02.0210
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0210
Cancer of Colon
[description not available]		02.0210
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0210
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		02.6530
Brain Inflammation
[description not available]		03.2260
Encephalitis
Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.		08.2260
Experimental Mammary Neoplasms
[description not available]		02.8840
Furrow Keratitis
[description not available]		01.9610